Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs

Next-generation sequencing is a powerful tool that can identify mutations or fusions in a wide range of cancers, enabling physicians to provide targeted therapy to patients and improve outcomes. In this vodcast, Professor Andrew Beggs discusses practical aspects of this technique from the clinical viewpoint. 

00:00 – Introduction from Professor Beggs
02:00 – Biopsy types for NGS
06:50 – DNA versus RNA for analysis
12:37 – Processing considerations – an NHS case study
15:30 – Integrating genomic profiling into patient care and management
22:12 – Conclusions

Speaker

• Prof. Andrew Beggs
  Institute of Cancer and Genomic Sciences, University of Birmingham, UK. Read more

Speaker disclosures

• Grant funding: AstraZeneca Plc, Incyte Inc, MSD, Moderna, Oxford Nanopore, Thermo Scientific, Illumina, BioNano, Innova Medical
• Travel & conference funding: Oxford Nanopore, Thermo Scientific, Illumina, Bayer
• Consultancy: Oxford Nanopore, Check4Cancer, Kiffik Biomedical, 2CureX Ag
• In kind support: MGITech, Illumina, Congenica, Qiagen 
• Salary support: MRC Senior Clinical Fellowship

Financial disclosure 

This content is intended only for healthcare providers, excluding UK, and was made possible by educational funding provided by Illumina, Inc., and Eli Lilly and Company.

Disclaimer

Any information provided and opinions expressed do not necessarily reflect the views of Springer Medizin GmbH. Springer Medizin GmbH and its employees, agents and subcontractors are not responsible or in any way liable for the currency of the information, for any errors, omissions or inaccuracies, or for any consequences arising therefrom. Inclusion or exclusion of any product does not imply its use is either advocated or rejected. Use of trade names is for product identification only and does not imply endorsement. Please consult the latest prescribing information from the manufacturer before issuing prescriptions for any products mentioned.